[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-blood-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-blood-loss":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100498781","phase-1-tranexamic-acid-in-rhinoplasty-perioperative-bleeding-edema-and-ecchymosis-100498781",false,"NCT05774717","Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis","Inclusion Criteria:\n\n* Adults at least 18 years of age who elect to undergo cosmetic or functional open primary rhinoplasty with osteotomies (repositioning the nasal bones) by Drs. Yang or Patel at VUMC.\n* No other facial plastics procedure nor sinus surgery performed simultaneously\n* Lack all the below Exclusion Criteria\n\nExclusion Criteria:\n\n* Known allergy to TXA (tranexamic acid)\n* Intracranial bleeding\n* Known defective color vision\n* History of venous or arterial thromboembolism\n* Active thromboembolic disease\n* Severe renal impairment (diagnosis of chronic kidney disease)\n* History of coagulation disorder\n* Known thrombocytopenia (platelets \\\u003C150,000)\n* Current use of anticoagulant (blood thinner)\n* Uncontrolled DM (diabetes mellitus) preventing use of dexamethasone in the perioperative period\n* Cardiac arrhythmia\n* History of AMI (acute myocardial infarction), stroke, seizure, liver failure\n* Laboratory results showing platelets \\\u003C150,000, PT (prothrombin time) \\>45, INR (international normalized ratio) \\>1.2, seizure disorder",true,"ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study will be a prospective randomized study to evaluate the effect of tranexamic acid (TXA) use on intraoperative and postoperative outcomes among patients undergoing rhinoplasty by two Facial Plastic surgeons at Vanderbilt. Outcomes will include intra- and post-operative bleeding and postoperative bruising and swelling.",[26,27],"Surgery","Postoperative Blood Loss","RECRUITING","2026-05-05",{"date":31,"type":32},"2026-05-07","ACTUAL",{"date":34,"type":32},"2023-04-01",{"date":36,"type":20},"2029-04-01",{"name":38,"class":39},"Vanderbilt University Medical Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100605575","comparative-study-of-tranexamic-acid-dosing-in-cardiac-surgery-100605575","NCT07164300","Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery","Comparative Study of Tranexamic Acid Dosage Regimens in Patients Undergoing Cardiac Surgery Under Cardiopulmonary Bypass","Inclusion Criteria:\n\n* Patients undergoing elective cardiac surgery using cardiopulmonary bypass\n* Patients to have discontinued anticoagulant and antiplatelet therapy preoperatively according to guidelines.\n\nExclusion Criteria:\n\n* Age below 18 years\n* Patient refusal\n* Pregnancy\n* End-stage renal disease\n* History of epilepsy,\n* Cardiac surgery without the use of cardiopulmonary bypass (off-pump)\n* Emergency operations\n* Known allergy to the administered agents.","99 Years",{"count":50,"type":20},150,[52],"NA","Tranexamic axid is routinely used as an antifibrinolytic agent in cardiac surgery to reduce the risk of blood loss and transfusion. However, there is no consensus regarding the dosage regimen of tranexamic acid that should be administered. The purpose of this study is to compare different dosages of tranexamic acid in cardiac surgery using cardiopulmonary bypass regarding the duration of inhibition of fibrinolysis as measured by the ClotPro test.\n\nBlood samples will be taken from the arterial line placed in the patient at specified time points in order to perform viscoelastic tests (ClotPro, TPA test), to detect successful inhibition of fibrinolysis and to measure tranexamic acid levels in the patient's blood. In case the action of tranexamic acid stops early postoperatively an additional dose of the medication will be administered to the patient.",[55,27,56,57,58],"Blood Coagulation Disorder","Adverse Drug Event","Fibrinolysis; Hemorrhage","Tranexamic Acid Adverse Reaction","2025-09-05",{"date":61,"type":32},"2025-09-10",{"date":63,"type":32},"2024-05-14",{"date":65,"type":20},"2027-12-15",{"name":67,"class":39},"University of Ioannina",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":40},"100442880","phase-2-effect-of-early-administration-of-txa-in-adult-hip-fractures-100442880","NCT05047133","Effect of Early Administration of TXA in Adult Hip Fractures","Does Early Administration of Tranexamic Acid Decrease Perioperative Blood Loss in Addition to Intraoperative Tranexamic Acid for Hip Fracture Patients?","Inclusion Criteria:\n\n* 1\\. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation\n\nExclusion Criteria:\n\n1. Polytrauma patients\n2. Previous operation on the ipsilateral hip\n3. Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)\n4. Patients with \\\u003C 6-month history of thromboembolic event (DVT\u002FPE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)\n5. History of seizure disorder\n6. Patients on birth control\n7. Pregnant Women\n8. Prisoners\n9. Active thromboembolic disease (DVT\u002FPE, MI, Stroke)",{"count":76,"type":20},170,[78,79],"PHASE2","PHASE3","This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.",[27],"2021-09-14",{"date":84,"type":32},"2021-09-16",{"date":86,"type":32},"2021-09-01",{"date":88,"type":20},"2022-07-01",{"name":90,"class":91},"Ascension Health","INDUSTRY"]